Strong Performance in Process Chromatography
Process chromatography experienced strong double-digit growth on a year-over-year basis due to the timing of customer orders within the quarter.
Progress in Droplet Digital PCR Strategy
Meaningful progress was made in advancing the Droplet Digital PCR strategy, including global sales training on new QX platforms and expanding partnerships with Gencurix and Biodesix.
Increase in Non-GAAP Operating Margin
Non-GAAP operating margin increased to 11.8% in Q3 2025 compared to 11.3% in Q3 2024, reflecting proactive cost management.
Maintained Full Year Guidance
Bio-Rad maintained its 2025 full year outlook with total currency-neutral revenue growth to be in the range of flat to 1%.